CTOs on the Move

Vor Biopharma

www.vorbio.com

 
Vor Biopharma is pioneering engineered hematopoietic stem cells (eHSCs) to dramatically change the treatment paradigm for hematological cancers. Vor`s eHSCs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. Vor`s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments. A proof-of-concept study for Vor`s lead program has been published in ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vorbio.com
  • 100 Cambridgepark Drive Suite 400
    Cambridge, MA USA 02140
  • Phone: 617.655.6580

Executives

Name Title Contact Details
Hunt Grobert
 Associate Director, IT Operations & Security Profile
Sadik Kassim
 Chief Technology Officer Profile
Sadik Kassim
 Chief Technology Officer Profile

Funding

Vor Biopharma raised $42M on 02/14/2019
Vor Biopharma raised $110M on 07/07/2020

Similar Companies

Folio Conversant

Folio Conversant is the premier provider of research services and biospecimen solutions. We offer an extensive array of quality biospecimens, particularly Human tissue and biofluids, supported by comprehensive laboratory and analytical services. Science does not stand still. Our goal is to become a key partner in supporting your team`s research and development in order to accelerate new diagnostic and therapeutic options for patients.

H and R Healthcare Inc

H and R Healthcare Inc is a Lakewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beacon Biotechnology

Beacon Biotechnology is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AMIGENICS

AMIGENICS is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.